Table 3.
Clinical features of cinacalcet-treated and control patients at the time of kidney transplantation
| Cinacalcet (n=36) | Controls (n=61) | p | |||
|---|---|---|---|---|---|
| Recipient | Age at Tx | (years) | 50.2 ± 10.3 | 49 ± 13.5 | 0.92 |
| Sex ratio | (% female) | 47 | 41 | 0.55 | |
| Dialysis vintage | (years) | 3.7 ± 2.1 | 3.3 ± 3.8 | 0.57 | |
| Resting diuresis | (ml) | 430 ± 655 | 444 ± 541 | 0.91 | |
| Multi-organ Tx | (%) | 5.6 | 1.7 | 0.28 | |
| Donor | Age | (years) | 46.8 ± 11.4 | 47 ± 11.4 | 0.93 |
| Sex ratio | (% female) | 42 | 46 | 0.67 | |
| LD | (%) | 2.8 | 1.6 | 0.70 | |
| DCD | (%) | 30.6 | 21.3 | 0.31 | |
| Transplantation | CIT | (min) | 779 ± 297 | 825 ± 255 | 0.43 |
| HLA mismatches | A | 0.8 ± 0.5 | 0.9 ± 0.5 | 0.75 | |
| B | 1.2 ± 0.7 | 1 ± 0.5 | 0.08 | ||
| DR | 0.8 ± 0.4 | 0.8 ± 0.3 | 0.99 |
Tx, transplantation; LD, living donor; DCD, donation after cardiac death; CIT, cold ischemic time; HLA, human leukocyte antigen.